You can buy or sell ODT and other stocks, options, ETFs, and crypto commission-free!
Odonate Therapeutics, Inc. Common Stock, also called Odonate Therapeutics, is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. Read More It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Guru FocusMar 11
Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.6 million of Shares
CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 140,000 shares of ODT on 03/08/2019 at an average price of $18.26 a share.
Simply Wall StMar 8
Did Changing Sentiment Drive Odonate Therapeutics’s (NASDAQ:ODT) Share Price Down By 40%?
Odonate Therapeutics, Inc. (NASDAQ:ODT) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. In fact the stock is down 40% in the last year, well below the market return. View our latest analysis for Odonate Therapeutics Odonate Therapeutics hasn’t yet reported any revenue yet, so it’s as much a business idea as a business. We can’t help wondering why it’s publicly listed so early in its j...
Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. Eastern Time. About Odonate Therapeutics, Inc. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and ext...
Expected May 2, Pre-Market